« Previous
Next »
Gastroenterology
Volume 136, Issue 2
, Pages
441-450.e1
, February 2009
Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
-
Percentage of patients in remission (endoscopic grade score of i0 or i1) vs recurrence (endoscopic grade score of i2, i3, or i4) of Crohn's disease at the 1-year endoscopic evaluation by random assign
Percentage of patients in remission (endoscopic grade score of i0 or i1) vs recurrence (endoscopic grade score of i2, i3, or i4) of Crohn's disease at the 1-year endoscopic evaluation by random assignment to infliximab or placebo. Infliximab vs placebo: P = .0006.
-
Endoscopic grade and percentage of patients with endoscopic recurrence of Crohn's disease at 1-year follow-up evaluation by random assignment to infliximab or placebo.Endoscopic grade and percentage of patients with endoscopic recurrence of Crohn's disease at 1-year follow-up evaluation by random assignment to infliximab or placebo.
-
CDAI scores of individual study patients at baseline and throughout the 1-year follow-up period by random assignment to (A) infliximab (n = 10) vs (B) placebo (n = 13). Two infliximab patients had theCDAI scores of individual study patients at baseline and throughout the 1-year follow-up period by random assignment to (A) infliximab (n = 10) vs (B) placebo (n = 13). Two infliximab patients had their last CDAI score carried forward beginning at weeks 30 and 46; 1 placebo patient had the last CDAI score carried forward beginning at week 36.
The authors disclose no conflicts.
This work was funded in part by an unrestricted grant from Centocor, Inc Miguel Regueiro, Scott Plevy, and Leonard Baidoo participate or participated as a consultant or speaker for Centocor, Inc.
Registered with www.clinicaltrials.gov (NCT00688636).
PII: S0016-5085(08)01889-1
doi: 10.1053/j.gastro.2008.10.051
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Gastroenterology
Volume 136, Issue 2
, Pages
441-450.e1
, February 2009

